The CD28 Related Molecule ICOS: T Cell Modulation in the Presence and Absence of B7.1/2 and Regulational Expression in Multiple Sclerosis
Overview
Authors
Affiliations
Costimulatory signals play a key role in regulating T cell activation and are believed to have decisive influence in the inciting and perpetuating cellular effector mechanisms in autoimmune diseases such as multiple sclerosis (MS). Inducible costimulator protein (ICOS), a recently identified member of the CD28-family, presumably affects the differentiation of Th1/Th2 cells after primary activation and modulates the immune response of effector/memory T cells. This study examines the expression and functional role of ICOS costimulation in healthy donors and patients with MS. After nonspecific or antigen-specific stimulation, ICOS is preferentially expressed on CD4 Th2-T cells. ICOS-costimulation affects the production of Th1 and Th2 cytokines both in the absence and presence of B7/CD28 costimulation, thus suggesting that ICOS costimulation can modulate cytokine secretion also in a CD28-independent manner. Levels of constitutive and inducible ICOS expression on human T cell subsets from peripheral blood were quantified in healthy donors and patients with MS. Constitutive expression of ICOS on T cells varies between 0.1% and 42.3%. There were no significant differences between both groups in the baseline expression or inducibility of ICOS on CD4 or CD8 T cells. ICOS expression could be demonstrated on CSF T lymphocytes in patients with acute MS relapses but was not elevated compared with peripheral blood. In essence we show that ICOS is upregulated on human T cells after stimulation and can modulate both Th1 and Th2 cytokine production in the absence and presence of B7-costimulation. In MS patients we demonstrate the functionality of the ICOS costimulatory pathway. Potential implications of ICOSL/ICOS interactions for MS immunopathogenesis are discussed.
Jiang M, Cai R, Wang J, Li Z, Xu D, Jing J Front Immunol. 2021; 12:685400.
PMID: 34354706 PMC: 8329850. DOI: 10.3389/fimmu.2021.685400.
Immune modulating peptides for the treatment and suppression of multiple sclerosis.
Badawi A, Siahaan T Clin Immunol. 2012; 144(2):127-38.
PMID: 22722227 PMC: 3415220. DOI: 10.1016/j.clim.2012.05.010.
[Multiple sclerosis: potential therapeutic options and update of ongoing studies].
Wiendl H, Lehmann H, Hohlfeld R, Hartung H, Kieseier B Nervenarzt. 2004; 75(6):536-52.
PMID: 15257377 DOI: 10.1007/s00115-003-1665-4.